Recommended and prevalent use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in a national population-based sample[J]
EBioMedicine 63:103202 Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hbscher SG, Newsome PN, (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
When responding to soft tissue ischemia, this alteration renders diabetic wounds incapable of upregulating vascular endothelial growth factor (VEGF), creating obstacles to angiogenesis and wound healing 6
sustained benefits with consistent use